secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001437749-26-009060
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q4 product sales $21.3M (+83% YoY); guides FY26 rev >$110M, 30%+ EBITDA margin
--------------------------------------------------------------------------------

- Q4 product sales $21.3M (+83% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.19; Adj. EBITDA $6.2M
- Launched DESMODA (first FDA-approved desmopressin oral solution) on March 9, 2026
- Acquired U.S. rights to Orphan Drug HEMANGEOL; relaunch May 1, 2026; accretive to 2026 earnings
- FY 2026 guidance: revenue >$110M, Adj. EBITDA margin >30%
- Cash $25.9M at Dec 31, 2025; net income $1.5M vs loss $5.4M prior year

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/0001437749-26-009060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/eton20251117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer